Differential Leukocyte and Platelet Profiles in Distinct Models of Traumatic Brain Injury by Hubbard, William Brad et al.
University of Kentucky 
UKnowledge 
Spinal Cord and Brain Injury Research Center 
Faculty Publications Spinal Cord and Brain Injury Research 
2-26-2021 
Differential Leukocyte and Platelet Profiles in Distinct Models of 
Traumatic Brain Injury 
William Brad Hubbard 
University of Kentucky, bradhubbard@uky.edu 
Meenakshi Banerjee 
University of Kentucky, reach.meenakshi@uky.edu 
Hemendra J. Vekaria 
University of Kentucky, hemendravekaria@uky.edu 
Kanakanagavalli Shravani Prakhya 
University of Kentucky, shravani.prakhya@uky.edu 
Smita Joshi 
University of Kentucky, smita.joshi@uky.edu 
See next page for additional authors Follow this and additional works at: https://uknowledge.uky.edu/scobirc_facpub 
 Part of the Medical Biochemistry Commons, Neurology Commons, Neurosciences Commons, and the 
Ophthalmology Commons 
Right click to open a feedback form in a new tab to let us know how this document benefits you. 
Repository Citation 
Hubbard, William Brad; Banerjee, Meenakshi; Vekaria, Hemendra J.; Prakhya, Kanakanagavalli Shravani; 
Joshi, Smita; Wang, Qingjun; Saatman, Kathryn E.; Whiteheart, Sidney W.; and Sullivan, Patrick G., 
"Differential Leukocyte and Platelet Profiles in Distinct Models of Traumatic Brain Injury" (2021). Spinal 
Cord and Brain Injury Research Center Faculty Publications. 37. 
https://uknowledge.uky.edu/scobirc_facpub/37 
This Article is brought to you for free and open access by the Spinal Cord and Brain Injury Research at UKnowledge. 
It has been accepted for inclusion in Spinal Cord and Brain Injury Research Center Faculty Publications by an 
authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu. 
Differential Leukocyte and Platelet Profiles in Distinct Models of Traumatic Brain 
Injury 
Digital Object Identifier (DOI) 
https://doi.org/10.3390/cells10030500 
Notes/Citation Information 
Published in Cells, v. 10, issue 3, 500. 
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. 
This article is an open access article distributed under the terms and conditions of the Creative 
Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). 
Authors 
William Brad Hubbard, Meenakshi Banerjee, Hemendra J. Vekaria, Kanakanagavalli Shravani Prakhya, 
Smita Joshi, Qingjun Wang, Kathryn E. Saatman, Sidney W. Whiteheart, and Patrick G. Sullivan 
This article is available at UKnowledge: https://uknowledge.uky.edu/scobirc_facpub/37 
cells
Article
Differential Leukocyte and Platelet Profiles in Distinct Models
of Traumatic Brain Injury
William Brad Hubbard 1,2,3,4 , Meenakshi Banerjee 5,† , Hemendra Vekaria 1 , Kanakanagavalli
Shravani Prakhya 5, Smita Joshi 5, Qing Jun Wang 6, Kathryn E. Saatman 1,2, Sidney W. Whiteheart 4,5
and Patrick G. Sullivan 1,3,4,*


Citation: Hubbard, W.B.; Banerjee,
M.; Vekaria, H.; Prakhya, K.S.; Joshi,
S.; Wang, Q.J.; Saatman, K.E.;
Whiteheart, S.W.; Sullivan, P.G.
Differential Leukocyte and Platelet
Profiles in Distinct Models of
Traumatic Brain Injury. Cells 2021, 10,
500. https://doi.org/10.3390/
cells10030500
Academic Editor: Yidong Bai
Received: 20 November 2020
Accepted: 18 February 2021
Published: 26 February 2021
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affil-
iations.
Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
1 Spinal Cord and Brain Injury Research Center (SCoBIRC), University of Kentucky, Lexington, KY 40536, USA;
bradhubbard@uky.edu (W.B.H.); hemendravekaria@uky.edu (H.V.); k.saatman@uky.edu (K.E.S.)
2 Department of Physiology, University of Kentucky, Lexington, KY 40508, USA
3 Department of Neuroscience, University of Kentucky, Lexington, KY 40508, USA
4 Lexington Veterans’ Affairs Healthcare System, Lexington, KY 40502, USA; whitehe@uky.edu
5 Department of Molecular and Cellular Biochemistry, University of Kentucky, Lexington, KY 40536, USA;
meenakshi.banerjee@utah.edu (M.B.); shravani.prakhya@uky.edu (K.S.P.); smita.joshi@uky.edu (S.J.)
6 Department of Ophthalmology and Visual Sciences, University of Kentucky, Lexington, KY 40536, USA;
qingjun.wang@uky.edu
* Correspondence: patsullivan@uky.edu; Tel.: +1-859-323-4684
† Current address: Department of Internal Medicine and Molecular Medicine Program, University of Utah, Salt
Lake City, UT 84112, USA.
Abstract: Traumatic brain injury (TBI) affects over 3 million individuals every year in the U.S. There
is growing appreciation that TBI can produce systemic modifications, which are in part propagated
through blood–brain barrier (BBB) dysfunction and blood–brain cell interactions. As such, platelets
and leukocytes contribute to mechanisms of thromboinflammation after TBI. While these mechanisms
have been investigated in experimental models of contusion brain injury, less is known regarding
acute alterations following mild closed head injury. To investigate the role of platelet dynamics
and bioenergetics after TBI, we employed two distinct, well-established models of TBI in mice: the
controlled cortical impact (CCI) model of contusion brain injury and the closed head injury (CHI)
model of mild diffuse brain injury. Hematology parameters, platelet-neutrophil aggregation, and
platelet respirometry were assessed acutely after injury. CCI resulted in an early drop in blood
leukocyte counts, while CHI increased blood leukocyte counts early after injury. Platelet-neutrophil
aggregation was altered acutely after CCI compared to sham. Furthermore, platelet bioenergetic
coupling efficiency was transiently reduced at 6 h and increased at 24 h post-CCI. After CHI, oxidative
phosphorylation in intact platelets was reduced at 6 h and increased at 24 h compared to sham. Taken
together, these data demonstrate that brain trauma initiates alterations in platelet-leukocyte dynamics
and platelet metabolism, which may be time- and injury-dependent, providing evidence that platelets
carry a peripheral signature of brain injury. The unique trend of platelet bioenergetics after two
distinct types of TBI suggests the potential for utilization in prognosis.
Keywords: neutrophil; platelet-neutrophil aggregate; bioenergetics; Seahorse; respirometry; con-
trolled cortical impact; mild TBI
1. Introduction
Traumatic brain injury (TBI) continues to be a significant world-wide clinical problem
that affects millions of individuals each year. While there remains a lack of FDA-approved
pharmaceuticals for TBI treatment, the on-going understanding of the underlying pathobi-
ology of head trauma not only identifies therapeutic targets but also pinpoints new avenues
for TBI prognosis. Distinct pathological hallmarks, such as mitochondrial deficits and
vascular damage, have been identified as major mechanisms of TBI [1–7]. Early blood–
brain barrier (BBB) impairment propagates interaction and infiltration of blood cells within
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the brain parenchyma, a process that is tightly regulated by the highly selective barrier
under normal conditions [8]. After TBI, platelets and leukocytes attach to the vascular
walls and aggregate in the injured cerebral tissue while also inducing inflammatory and
immune responses [9–11]. Indeed, we have described BBB dysfunction following TBI as
the epicenter for mechanisms of inflammation and thrombosis, which are mediated in part
by platelets and leukocytes [12]. Thromboinflammation is among a variety of systemic
pathologies that are now widely appreciated as potential consequences of TBI.
Alterations of platelet physiology have been reported clinically following severe TBI.
Platelet dysfunction, characterized by inhibition of platelet arachidonic acid (AA) and
ADP receptors leading to lower levels of AA/ADP-induced platelet activation, occurs
early after severe TBI without major systemic trauma [13,14]. This inhibition appears to be
dependent on TBI severity, with mild TBI demonstrating lower levels of platelet receptor
inhibition [15]. TBI, by itself, results in increased bleeding time, or hypocoagulation, early
after injury, which is indicative of deficits in coagulation pathways or platelets’ ability to
activate [14]. TBI also results in AA platelet receptor downregulation in the first few days
following injury [16]. Importantly, there are shifts between hypocoagulable and hypercoag-
ulable states following TBI [17]. Preclinical studies recapitulated these findings in murine
models of moderate-to-severe TBI. These studies demonstrate immediate hypocoagulation
followed by delayed hypercoagulation events [18–22]. Recently, one preclinical study
showed changes acutely after closed head injury (CHI), demonstrating hypercoagulability
and increased aggregation of platelets at 6 h after CHI [19]. It is important to understand
platelet dynamics to fully appreciate mechanisms of thromboinflammation.
Several neurodegenerative diseases and pathologies have utilized platelet function as a
biomarker of injury progression. Platelet respiration is an emerging pathological biomarker
as it can serve as a systemic marker for underlying mitochondrial dysfunction in metabolic
tissues, such as the brain [23]. The concept that mitochondrial function in platelets can
exemplify deficits in cerebral bioenergetics during neurological disease progression is not
entirely new [24]; early work showed that Complex I activity is reduced in platelets of
patients with idiopathic Parkinson’s disease [25]. Furthermore, this has been appreciated
in the context of Alzheimer’s disease (AD) through decreased Complex IV activity in
platelets of AD patients [26,27]. Maximal respiratory capacity in platelets correlates with
respiratory control ratio (RCR) of mitochondria in skeletal and cardiac muscle [28] in
addition to the brain [29]. Furthermore, changes in platelet coupling efficiency after cardiac
arrest have been shown to represent underlying cerebral bioenergetic dysfunction [30].
We have shown acute mitochondrial impairment following both single and repeated mild
TBI [2] and metabolic deficiencies that continue long-term following mild TBI [1]. Although
platelet respiration shows promise as a peripheral monitor of neurodegenerative disease,
no research, to date, has examined platelet bioenergetics within the context of TBI.
TBI presents clinically in a highly heterogeneous fashion, in terms of severity, symp-
tomatic onset/progression, and underlying pathology. Even TBIs that are classified under
the same Glasgow Coma Scale (GCS) score vary widely in terms of underlying pathol-
ogy [31]. The pathologies and secondary injury mechanisms consist of multiple endophe-
notypes, such as bioenergetic dysfunction, vascular damage, and thromboinflammation.
Therefore, injury-associated markers are necessary to systematically monitor these en-
dophenotypes and, therefore, specific aspects of neurologic injury and recovery. This is
also crucial in the context of repetitive mild head injury. Since repeated mild TBI results in
worsened or prolonged outcomes [32], it is pertinent to track recovery following a mild TBI.
Current return-to-play and return-to-duty guidelines for athletes and military service mem-
bers, respectively, are put in place to prevent the additive effects of head trauma [33]. These
are based upon memory recall and concentration compared with baseline assessments.
However, cognitive recovery and symptom resolution do not necessarily equate to neuronal
recovery [34]. Therefore, objective biomarkers that mirror deficits in cerebral metabolism
after mild TBI are needed to assess sufficient brain recovery. We, therefore, focused on
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platelet function to further our understanding of metabolic alterations systemically after
head trauma.
There are several characterized preclinical models of TBI that focus on replicating
certain distinct aspects of clinical TBI. In the current study, we focus on head injury models
that induce brain injury via compressive mechanical force. Other preclinical models, such
as the closed-head impact model of engineered rotational acceleration (CHIMERA), involve
shear deformation forces generated by rapid acceleration/deceleration of the head, which
is a component of human TBI. Nevertheless, these compressive injury models indeed
replicate clinical aspects of TBI-induced outcomes, such as behavioral deficits, axonal
injury, inflammation, and metabolic dysfunction [2,35–38]. The controlled cortical impact
(CCI) model involves impact directly to the dura of the brain producing a relatively defined,
focal cortical contusion that results in cortical and hippocampal neurodegeneration at the
site of injury. CCI can be graded in terms of severity by modifying the parameters of impact,
namely depth of piston entry into the brain parenchyma. CCI produces mitochondrial
dysfunction, neuroinflammation, neuronal death, and intracerebral hemorrhage. The CHI
model involves a midline impact to the skull, which generates a relatively diffuse brain
injury that produces neuroinflammation and deficits in brain metabolism. CHI typically
does not produce overt brain hemorrhage or cell death.
To examine blood cell changes after TBI, we utilize these two distinct models of
experimental brain injury to monitor the acute profile of leukocyte and platelet activity. We
hypothesize that blood cell dynamics are altered transiently following TBI, in a manner
dependent upon injury model. Furthermore, alterations in blood cell dynamics can impart
understanding of mechanisms of thromboinflammation and coagulopathy.
2. Materials and Methods
2.1. Experimental Design
All of the studies performed were approved by the University of Kentucky Institu-
tional Animal Care and Use Committee (IACUC). Additionally, the Division of Laboratory
Animal Resources at the University is accredited by the Association for the Assessment and
Accreditation for Laboratory Animal Care, International (AAALAC, International) and all
experiments were performed within its guidelines. All animal experiments complied with
ARRIVE (Animal Research: Reporting of In Vivo Experiments) guidelines and experiments
were carried out in accordance with the National Institutes of Health Guide for the Care
and Use of Laboratory Animals (NIH Publications No. 8023, 8th edition, revised 2011).
All experiments were conducted using male C57BL/6J mice (2–3 months old; Jackson
Laboratories, Bar Harbor, ME).
Animals were randomly assigned to groups and all data analyses were performed
blinded to treatment groups. Experimental groups were euthanized at either 6 or 24 h
after TBI or sham injury. The animals were housed five per cage and maintained in a 14 h
light/10 h dark cycle. All animals were fed a balanced diet ad libitum and water was
reverse osmosis-generated. For all outcomes, experiments were conducted with biological
replicates of n = 5–10/group. Additionally, technical triplets were used in each assay.
2.2. Controlled Cortical Impact
The CCI procedure was performed according to past studies [35,36]. Prior to injury,
animals were anesthetized using 2–5% isoflurane and their heads were shaved and placed
in a Kopf stereotaxic frame for proper positioning under a pneumatic impactor (TBI-0310
Impactor, Precision Systems and Instrumentation (PSI), Fairfax, VA, USA). The animals’
body temperature was maintained at 37 ◦C with the use of an isothermal pad. Artificial
tears were placed in their eyes and anesthesia was maintained at 2–3% isoflurane during
the procedure. Prior to scalp incision, the scalp was cleaned with betadine and 200 µL
of a 10% local anesthetic in saline solution (Sensorcaine-MPF (Bupivacaine HCl) 0.5%
(Henry Schein Animal Health, Dublin, OH, USA) and Epinephrine 1:200,000) was injected
subcutaneously at the site. A 3-mm craniotomy was performed lateral to the midline on the
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left side of the skull centered between lambda and bregma, without disrupting the dura.
CCI groups received a unilateral injury, classified as severe (1.0 mm depth of contusion
at 3.5 m/sec with a dwell time of 500 msec), directly to the surface of the brain using a
2 mm impactor tip. Sham animals received a craniotomy but did not receive an impact to
the brain. Following the injury, the craniotomy was covered with an absorbable hemostat
(Surgicel), followed by a sterilized plastic surgical cap, and incisions were then closed
with surgical staples. Mice were taken off isoflurane exposure and were removed from the
stereotaxic frame. Mice were then placed in a clean cage that was temperature-controlled
at 37 ◦C with a heating pad until the animals were mobile and fully responsive.
2.3. Closed Head Injury
Mice were subjected to CHI based on previous studies [2,39]. Following induction
of anesthesia in a chamber using 3% isoflurane for 1–2 min and shaving of the head,
mice were transferred into a stereotaxic frame with non-rupture Zygoma ear cups (Kopf,
Instruments, Tujunga, CA, USA) where anesthesia was maintained using 2.5% isoflurane
delivered via a nose cone. The surgical area of the scalp was cleaned with a betadine
solution. Following injection of 0.2 mL 1:200,000 epinephrine and 0.5% bupivacaine in
sterile, normal saline for local analgesia, the scalp was resected. Mice then received a mild
CHI using a pneumatically controlled cortical impact device (TBI-0310 Impactor, PSI) with a
custom made, 5 mm diameter, pliant, silicone tip with a hardness of 55 Shore A. The tip was
aligned along the midline suture between the bregma and lambda sutures with the edge
of the tip lined up with the lambda suture. The device was programmed to impact at an
intended depth (2.0 mm) at a 3.5 m/sec velocity with a 500 msec dwell time. Sham-injured
mice received anesthesia and underwent the same surgical procedure without receiving an
impact. The total duration of anesthesia was controlled for all animals to be 10 min. To
assess loss of consciousness, mice were immediately removed from the stereotaxic device
after impact and placed onto a heating pad on their backs. Apnea duration and time to
right spontaneously to a prone position (righting reflex) were assessed. After righting,
mice were briefly re-anesthetized to suture their scalps and returned to the heating pad to
fully recover. Mice were injected (subcutaneous; s.c.) with 1 mL of sterile, normal saline to
increase hydration, encouraging a normal eating response post-injury and maintenance of
healthy weight.
2.4. Mouse Platelet Isolation
At either 6 h or 24 h post-injury, animals were asphyxiated with CO2, and up to 1 mL
blood was collected via cardiac puncture. Blood was harvested using final concentrations
of 0.38% sodium citrate solution (supplemented with 0.2 U/mL apyrase and 10 ng/mL
prostacyclin (PGI2) (Cayman Chemical, Ann Arbor, MI, USA; Cat #18220)) in a 26G 3/8
syringe. Approximately 100 µL of whole blood was taken for hematology counts and
platelet-neutrophil aggregation (PNA) assays, while the remaining volume was used for
isolating platelets for Seahorse analysis. The 2 mL tube, containing blood for Seahorse
analysis, was centrifuged at 100× g for 10 min at room temperature (RT; 20 to 25 ◦C). After
centrifugation, the top yellow layer (platelet-rich plasma; PRP) was removed, being careful
not to take the thin buffy coat layer or dark red RBC layer, and transferred into 1.5 mL
tubes. The 1.5 mL tubes were centrifuged at 100× g for 10 min at RT. The supernatant
(PRP) was removed and transferred to 1.5 mL tubes. Prostacyclin (PGI2; 30 µL) was freshly
added from a stock solution (prepared as 1 mg/mL PGI2 in 50 mM Tris, pH 9.5) to a
phosphate/glucose buffer (50 mL 1X PBS, 45 mg glucose (5 mM)) at time of assay. This
phosphate-prostaglandin-glucose buffer (PPG) was added to increase the volume of PRP
four-fold and mixed gently with a pipette. The samples were centrifuged at 2000× g
for 1 min at RT. The tubes were then gently rotated and centrifuged again 2000× g for
5 min at RT. The supernatant (plasma) from this spin was removed with a pipette. The
remaining platelet pellets were resuspended in 1 mL of PPG buffer and then the tubes
were topped off with PPG buffer. The tubes were then centrifuged at 2000× g for 1 min
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at RT, rotated and centrifuged again at 2000× g for 2 min at RT. The supernatant from
this last spin was removed and discarded and the pellet resuspended in 50 µL PPG buffer.
Protein concentration was determined using BCA protein assay kit (Pierce, Cat # 23,227)
recording the absorbance at 560 nm on Biotek Synergy HT plate reader (Winooski, VT,
USA). Approximately 1 µg platelet protein corresponds to ~1 × 106 platelets, for which
platelet counts were measured using a Z2 Coulter Counter (Beckman Coulter, Inc., Miami,
FL, USA).
2.5. Hematology Analysis
Of the aliquoted 100 µL of whole blood, 50 µL was used to perform whole blood
counts, including red blood cells, white blood cells (leukocytes), platelets, and mean platelet
volume, using the IDEXX ProCyte Dx analyzer (IDEXX Laboratories, Westbrook, ME, USA).
2.6. Flow cytometry—Platelet-Neutrophil Aggregation
The remaining 50 µL of whole blood was taken for fluorescence-activated cell sorting
(FACS) studies. This assay was performed on live cells the day of blood collection. Whole
mouse blood was incubated with FITC-anti-CD41/61 (platelets) and APC-anti-Ly6G (neu-
trophils) antibodies for 30 min at RT (see Figure S2 for gating strategy). To lyse the red
blood cells, 1 mL of 1X BD FACS/Lyse Solution (BD Biosciences, San Jose, CA, USA; Cat No.
349202) was added to samples and incubated for 15 min at RT in dark. From this, 100 µL
was resuspended in 1 mL of PBS pH 7.4 and samples were analyzed on the BD LSRIITM
flow cytometer (BD Biosciences) and 500,000 events were acquired per sample with gating
around 50,000 granulocytes. Data were then analyzed using the FlowJo software (v7.6.5; BD
Biosciences). Quantification shows PNAs as measured by double-positive events for both
CD41/61 and Ly6G. Platelet-neutrophil dynamics were measured as: (% double-positive
events at 24 h post-injury) minus (% double-positive events at 6 h post-injury).
2.7. Measurement of Mouse Platelet Bioenergetics
One previous report demonstrated that pooling whole blood from up to five mice
would provide sufficient platelet numbers to examine respiration [40]. To our knowledge,
this is the first report demonstrating that platelet respiration from a single mouse can
be measured using the Seahorse XFe96 technology. Adequate resolution at low oxygen
consumption rates (OCRs) allows as little as 10 µg platelet protein (approximately 1 × 107
platelets) to be used in each well for oxygen consumption measurements [41].
Measurements of bioenergetics in platelets were completed using a Seahorse XFe96
Flux Analyzer (Agilent Technologies, Santa Clara, CA, USA). The OCR was measured in
the presence of substrates, inhibitors, and uncouplers related to OXPHOS as modified
from previously described methods [42,43]. The day before the planned experiment, the
sensor cartridge of Extracellular Flux kit was filled with 200 µL deionized water and kept at
37 ◦C overnight. At least 30 min prior to use, the water was removed, the plate filled with
200 µL XF calibrant solution and put back at 37 ◦C. The injection ports, A to D of the sensor
cartridge, were loaded separately or in combinations of substrates/inhibitors/uncouplers
to measure different states of respiration. Before loading, the stocks were diluted appropri-
ately in PPG buffer such that after each sequential injection, the final concentration of the
modulators was 5 mM pyruvate, 2.5 mM malate, and 10 mM succinate (via Port A), 5 µM
oligomycin A (via Port B), 4 µM FCCP (via Port C), and 1 µM antimycin A (via Port D).
Either 10 or 30 µg total platelet protein (approximately 1 × 107 or 3 × 107 platelets) was
loaded per well on a Seahorse XFe96 assay plate in a total volume of 30 µl (platelet sample
plus PPG buffer). The assay plates were centrifuged at 2100× g for 4 min at RT. Additional
pre-warmed PPG buffer was added to bring the starting volume to 175 µL. After the
calibration step, the utility plate was replaced by the assay plate carrying platelet samples.
Seahorse Standard XFe96 flux assay plates were utilized for platelet analysis. Oxygen
consumption rates (OCR) and extra-cellular acidification rate (ECAR) were recorded in the
absence or the presence of various substrates/inhibitors which were added from port A
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to port D. These measurements were performed on intact (non-permeabilized) platelets.
Basal readings were performed in the presence of glucose in the buffer. OXPHOS, LEAK,
MAX, and non-mitochondrial (NON-MITO) oxygen consumption respiration rates were
recorded based on subsequent port injections (Figure 1). Basal glycolysis was measured
as ECAR in the presence of glucose without substrate addition. Maximum glycolysis was
measured as ECAR after the addition of oligomycin according to the injection paradigm in
Figure 1. Platelet coupling efficiency was calculated by OXPHOS/LEAK, while glycolytic
reserve capacity was calculated by Max glycolysis-Basal glycolysis. Raw OCR and ECAR
values were used for analysis within a given experiment and reported in all figures.
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horse XFe96 Flux Analyzer enables the ass ssment of up to 30 independent samples in triplicate at one
time. For respiromet y of intac platelets, platelets were added in prostacyclin/phosphate/glucose
buff r; this state of respiration is defined as ROUTINE. For injection A, 5 mM pyruvate, 2.5 mM
malate, and 10 M succinate were added to give OXPHOSCI+CII of platelets. Oligomycin (5 µM)
was injected next to give LEAK platelet respiration. FCCP (4 µM) was then added in injection C
for MAXCI+CII. Finally, non-mitochondrial (NON-MITO) oxygen consumption, independent of the
electron transport system, is measured after addition of antimycin A (1µm).
2.8. Statistical nalysis
o er analysis was conducted for experimental data a priori based on an effect
size and expected dat variance. Statistical analysis was performed using Graph Pad
Prism 8 (GraphP d Softwar , San Diego, CA, USA) or JMP Pro 14 (SAS, ary, NC, USA).
For all analy es, the significance of differe ces among groups was set at p < 0.05. For
each measure, dat were measured using interv /ratio scales. The Brown–Forsythe and
Bartlett’s tests were perform d to ensure h mogeneity of variance. Furthermore, the
Shapiro–Wilk t st was completed to ensure normality. As these criteria were met for al
experimental data, parametric statistics were employed for all an lyses. For ata obtained
on PNAs, a statistic l blocking f ctor for assay day was utiliz d to reduce within group
variability betwee assays runs. For platel bioenergetics data, raw OCR/ECAR values
were used for analysis within a g ven experiment. For all analyses, unpair two- ailed
t-test was perf r ed to co pare sham and injured groups.
3. Results
3.1. CCI Does Not Change Platelet Parameters But Decreases Early Blood Leukocyte Levels
To assess the acute effects on peripheral blood cell profiles following CCI, we examined
hematological parameters at 6 and 24 h post-injury. There were no significant differences,
either at 6 or 24 h, for RBC counts (Figure 2). Leukocyte counts were significantly decreased
at 6 h post-CCI compared to sham (Figure 2). Systemic leukocyte counts were restored by
24 h post-injury. There were also no changes in platelet counts or mean platelet volume
(MPV) early after CCI.
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Figure 2. Early profile of blo d cell rations following contusion brain injury (CCI) and mild closed head impact
(CHI). (Top Panels) Mice received either sham injury or severe CCI followed by euthanasia at either 6 or 24 h post-injury.
Examination of RBC counts, WBC counts, platelet counts, and mean platelet volume (MPV) was performed by an IDEXX
ProCyte Dx Analyzer. CCI does not alter RBC counts, platelet counts, or platelet volume at 6 or 24 h after injury. However,
WBCs were significantly decreased after CCI compared to sham at 6 h post-i before restoration at 24 h post-injury.
** p = 0.0076; t = 3.083. n = 8–9/group. (Bottom Panels) Mice received either sham injury or mild CHI followed by euthanasia
at either 6 or 24 h post-injury. Examination of RBC counts, WBC counts, platelet counts, and mean platelet volume (MPV)
was performed. CHI does not significantly change RBC counts, platelet counts, or platelet volume at 6 or 24 h after injury.
However, WBCs were significantly increased after CHI compared to sham at both 6 and 24 h post-injury. ** p = 0.0039;
t = 4.009. * p = 0.048; t = 2.397. n = 4–5/gro p. Mea ± SEM.
3.2. CHI Does Not Alter Platelet Parameters But Rather Increases Blood Leukocyte Levels
Simil r to our previous reports [37], a single CHI resulted in an immediate apnea
respons (17.2 ± 3.0 s) and an increase in time right aft r a 10-minute ustain d bout
of an thesia (CHI: 5.0 ± 1.3 min vs. Sham: 1.3 ± 0.1 min). RBC counts were unchanged
early after CHI (Figure 2). However, we found significantly higher leukocytes counts in
the blood following CHI at both 6 and 24 h post-injury, compared to sham. This may
be an indication of a delayed immune response in the brain or leukocytosis induced by
diffuse mild TBI. We show that platelet counts and MPV are not changed at either 6 or 24 h
following CHI.
3.3. CCI Causes a Dynamic Shift in Early Platelet-Neutrophil Aggregation
Platelet-leukocyte aggregates are indicative of the thromboinflammatory response
following cerebral trauma [44]. Platelet-neutrophil aggregates (PNAs) represent the vast
majority of platelet-leukocyte aggregates; as such, PNAs have been shown to increase
following acute ischemic stroke [45]. Although we find that PNA levels are not significantly
different at either 6 or 24 h after CCI compared to sham, the change in PNAs between these
early time points was significantly different between sham and CCI (Figure 3).
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Figure 3. Divergent early profiles of platelet-neutrophil ag regati fter contusion brai injury and mild closed head
impact. (Top Panels) Mice received either sham injury or severe CCI followed by euthanasia at either 6 or 24 h post-injury.
FACS analysis was performed on blood samples to examine platelet-neutrophil aggregation. Representative dot plots
of flow cytometry showi g platelet-neutrophil aggregates (PNAs) in the top-right quadrant of each pl t. There were no
significant differences in PNAs after CCI at either 6 or 24 h post-injury when compared to time-matched sham controls.
There was a significant difference between sham and CCI groups in platelet-neutrophil dynamics (relative change of PNAs)
from 6 to 24 h post-injury. * p = 0.032. t = 2.373. n = 8–9/group. (Bottom Panels) Mice received either sham injury or mild
CHI followed by euthanasia at either 6 or 24 h post-injury. FACS analysis was performed on blood samples to examine
platelet-ne trophil aggregation. Representative dot plots of flow cytometry sh w g platelet-neutrophil aggregates (PNAs)
in the top-right quadrant of each plot. Levels of platelet-neutrophil aggregates (PNAs) was slightly elevated, though not
significantly different, in mice receiving CHI at both 6 and 24 h post-injury when compared to time-matched sham controls.
There was no significant difference between sham and CHI groups in the platelet-neutrophil dynamics from 6 to 24 h
post-injury. n = 5/group. Mean ± SEM.
3.4. CHI Does Not Alter Platelet-Neutrophil Aggregation Acutely After Injury
Although at both 6 and 24 h the mean PNA levels were higher for the CHI group
than the sham controls, this difference did not reach statistical significance (Figure 3). This
slight increase may be indicative of an early thromboinflammatory response following
CHI. There was no early shift in PNA levels between 6 and 24 h following CHI.
3.5. CCI Produces an Acute Shift in Platelet Coupling Efficiency
Metabolic changes in platelets, which may relate to disease progression [23], can be
readily assessed using respirometry techniques. Platelet respiratory parameters, such as
coupling efficiency and reserve capacity, were similar to previously published results [42].
As stated previously, this is the first study, to our knowledge, that demonstrates the
measurement of platelet respiration from a single mouse (versus pooled samples). There
were no changes in any platelet respiration state at either 6 or 24 h following CCI (Figure 4).
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However, the coupling efficiency of platelets was lower at 6 h and higher at 24 h after CCI
compared to sham (Figure 4). An expanded time course showed that coupling efficiency
returned to sham levels at 12 and 18 h post-injury before an increase at 24 h following CCI
(Figure S1), demonstrating a gradual transition acutely after CCI. The glycolytic signature
of platelets was unchanged after CCI (Figure 4).
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injury and mild closed head injury. (Top Panels) Mice received either sham injury or severe CCI followed by euthanasia
at either 6 or 24 h post-injury. Isolated platelets underwent respirometry using the Seahorse XFe96. At 6 or 24 h post-CCI,
there were no significant differences in any state of respiration measured. Platelet coupling efficiency was reduced 6 h
after CCI compared to sham. t = 2.656; * p = 0.012. There was a significant increase in platelet coupling efficiency 24
h after CCI compared to sham. t = 2.637; * p = 0.019. Platelet glycolysis was unchanged at 6 and 24 h after CCI. n =
6–10/group, (Bottom Panels) Mice received either sham injury or mild CHI followed by euthanasia at either 6 or 24 h
post-injury. Isolated platelets underwent respirometry using the Seahorse XFe96. At 6 h post-CHI, OXPHOSCI+CII was
significantly lower in the CHI group compared to sham. t = 2.284; * p = 0.040. In general, overall platelet respiration
was lower at 6 h after CHI compared to sham. At 24 h, post-CHI, MAXCI+CII was significantly higher in the CHI group
compared to sham. t = 3.12; * p = 0.0142. In general, overall platelet respiration was higher at 24 h after CHI compared
to sham. Platelet coupling efficiency was unchanged at 6 and 24 h after CHI. There was no significant difference in
platelet glycolysis at either 6 or 24 h following CHI. n = 5–8/group. Mean ± SEM.
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3.6. CHI Causes Early Alterations in Platelet Bioenergetics after Injury
After CHI, platelets displayed lower OXPHOS levels at 6 h post-injury compared with
sham (Figure 4). By 24 h, however, platelets from mice with CHI exhibit significantly higher
MAX respiration levels compared to those from sham mice (Figure 4). Neither platelet
coupling efficiency nor platelet glycolysis (Figure 4) changed acutely after CHI.
4. Discussion
This study shows that early blood cell dynamics are differentially altered between ex-
perimental contusion TBI and mild diffuse TBI. The two distinct injury models used in this
study represent differing injury severity, pathobiology, and spatial injury progression. The
immune response following CNS injury is initiated by damage- and pathogen-associated
molecular patterns (DAMPs/PAMPs), followed closely by neutrophil interactions in the
brain [46]. The exact progression of leukocyte mobilization or brain infiltration is not clear,
but we show in this study that these mechanisms are distinct between closed head impact
and contusion brain injury. Waves of early leukocyte infiltration into the brain, including
neutrophils (hours after injury) and monocytes/T lymphocytes (days after injury), are
well-documented following CCI [9,44,47]. Comparatively, leukocyte infiltration is modest
following CHI [10]. Our results show an early, transient decrease in leukocyte counts after
CCI. We also demonstrate that blood leukocyte levels increase at both 6 and 24 h after CHI
compared to sham. Clinically, blood leukocyte levels are increased early after TBI [48] and
this increase is dependent, to some extent, on injury severity [47]. Elevated blood leukocyte
levels, measured upon hospital admission, were identified as a prognostic biomarker for
severe head injury by correlating with an unfavorable outcome at 6 months post-injury [49],
though another study found no association with increased leukocyte counts and 6 month
outcome [50]. Blood leukocyte levels measured following CCI do not align with these
clinical findings. It has been shown that catecholamine released after TBI contributes to
leukocytosis, including mobilization of marginal or adherent leukocytes [51,52]. CHI may
induce leukocytosis, potentially via catecholamine release without early overt infiltration
into the brain. The large increases that we observed in blood leukocyte population after
CHI could be the physiologic mechanism for on-going or even delayed immune response
in the injured brain and are clinically relevant. Longitudinal studies to expand upon the
current results are needed.
Platelet-leukocyte interactions increase in environments of inflammation. It is well-
known that the influx of inflammatory blood cells occurs at the BBB after brain dam-
age [6,12] and this infiltration, which is propagated by the dysfunctional neurovascular
unit, contributes to on-going neuroinflammation [53,54]. In the current study, we demon-
strate how TBI can contribute to early systemic inflammation as well. Clinically, acute
platelet-leukocyte aggregation increases have been correlated with neurological deterio-
ration following ischemia [45]. Post-TBI microthrombi have been observed in the brain;
indeed, platelet-leukocyte interactions have been shown to promote thrombosis following
TBI [55]. We show a small, non-significant increase in PNA levels at 6 h after CCI with a
significant decline from 6 to 24 h post-CCI. These acute PNA dynamics need further inves-
tigation to understand their role in pathophysiology following CCI. Following CHI, slight,
though non-significant, increases in PNAs were observed acutely, which could be related to
elevated leukocyte levels in the blood after CHI. Future studies with extended time course,
and incorporation of repeated CHIs, are warranted to examine the temporal progression of
PNAs after TBI. Furthermore, platelets have been shown to propagate monocyte differenti-
ation into macrophages [56], so platelet interaction with monocyte/macrophage may also
be important following TBI and, in turn, influence the bioenergetic status of platelets.
While neuroimaging techniques, including computed tomography (CT), MRI, diffusion-
weighted imaging, and diffusion tensor imaging, are commonly used for diagnosis and
prognosis of TBI, these are not meant for point-of-care or longitudinal tracking. Serum and
cerebrospinal fluid (CSF) markers also are routinely used for diagnosis and prognosis of
TBI. As an alternative, platelets have been widely recognized to mirror the progression
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of neurological disease. As the pathobiology of TBI is dynamic, these biomarker-based
measures are just a glimpse of a continually evolving disease state. While serum biomark-
ers may have complex kinetics (release from the brain, crossing the BBB, and systemic
clearance), platelet function can be pathologically altered following interactions in the
damaged brain. We present initial findings of platelet alteration after TBI, but additional
research is needed. Indeed, future studies can be performed to monitor platelet function
with FACS-based techniques (collected serially) correlated to behavioral and histological
outcome as a “within subject” analysis. Additionally, RNA-seq could be employed to
build off of this work enabling biomarker discovery in the blood transcriptome following
TBI [57].
We show here that platelet counts and MPV are stable early after either CCI or CHI.
Previous studies showed that platelet counts are unaltered at 6 h following weight-drop
closed head impact [19]. Another study found no changes in platelet counts or MPV
after closed head TBI in the rat within 1 h after injury [18]. Hypercoagulability occurs
early following CHI, despite no alteration in platelet count [19]. Our results build upon
these findings and further demonstrate that changes in platelet function or metabolism are
independent of changes in platelet count or MPV.
To our knowledge, no study has been published on platelet bioenergetic changes
after TBI. We show distinct temporal alterations in platelet respiration in a model of mild
TBI at acute time points. It is known that platelet activation leads to increased oxidative
phosphorylation [58]. For example, the addition of thrombin increases OXPHOS, while
the addition of indomethacin inhibits platelet activity and decreases OXPHOS. After
closed head injury, we show that platelet respiration increases at 24 h, alluding to elevated
platelet activation and potentially mechanisms of delayed thrombosis after CHI. Following
contusion brain injury, platelet coupling efficiency is decreased at 6 h and increased at 24 h
after CCI.
Platelets are uniquely suited to play a variety of roles following TBI. Platelets, mea-
suring ~1–3 µm, have the ability to circulate in a majority of the brain microvasculature,
facilitating their critical role in vascular remodeling following injury [59,60]. As microvas-
cular injury is a hallmark of TBI, there is high potential for enhanced platelet-brain cell
communication in these compromised areas [5]. Platelets may play a major role in BBB
dysfunction after TBI. In areas of BBB breakdown, the glycoprotein Ib-IX-V complex on
the surface of platelets binds to von Willebrand factor (vWF) in the subendothelium [61].
The role of platelets goes well beyond that related to hemostasis following TBI; platelets
interact with the BBB and cerebral parenchyma after injury. It was recently reported that
platelet C-type lectin-like 2 (CLEC-2) receptors regulate the neuroinflammatory response
and integrity of the BBB following TBI [62]. Platelets can communicate with neurons
through release of microparticles, exosomes, and potentially neurogenic factors [63]. An-
other method of molecular communication is via damage-/pathogen-associated molecular
patterns (DAMP/PAMPS) that are released following TBI and induce a platelet-mediated
inflammatory response [64]. Platelet accumulation in regions of CNS damage helps pro-
mote neurogenesis and white matter repair [65].
It is interesting that decreased OXPHOS rates in platelets at 6 h precedes decreased
State III bioenergetics in the cortex at 24 h in the CHI model [2]. Platelets may sense
specific neuronal/glial populations near the vasculature to account for this discrepancy
in metabolic changes. Previously, it has been reported that maximal respiration of cor-
tical mitochondria from female green monkeys positively correlates with parameters of
platelet respiration [29]. Our group has shown dysfunction in brain mitochondria early
after both CCI and CHI [2,36]; further analysis will examine the correlation with platelet
bioenergetics after experimental TBI. We observe that platelet coupling increases at 24 h
after CCI, which coincides with decreased mitochondrial bioenergetics in the brain, as pre-
viously described [66]. This is consistent with acutely elevated platelet coupling efficiency
corresponding with lower cerebral bioenergetics in a model of cardiac arrest [30].
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Platelets are bioenergetically well-coupled compared to other blood cell types, demon-
strating higher ATP-linked respiration (OXPHOS) and lower LEAK respiration [42]. Platelets
are also more glycolytic compared to other blood cell types [42]. The lack of glycolytic alter-
ation in this current study suggests that platelet bioenergetic changes are occurring at the
mitochondrial level. Although no changes were seen in platelet glycolysis early after TBI,
it would be important to examine whether the glycolytic response to a cellular challenge
(e.g., agonists such as thrombin) is altered after TBI. It is plausible that platelets in TBI
subjects could be predisposed to altered metabolic responses. Furthermore, mitochondrial
dysfunction in platelets themselves could result in secondary coagulopathy, leading to
increased risk of thrombosis through activation and microparticle secretion [67].
Shifts in platelet respiration early after injury could be, in part, due to platelet turnover.
However, newly formed platelets may continue to interact with the dysfunctional BBB and
demonstrate altered bioenergetics. Alternatively, mitochondrial respiration alterations in
platelets could represent changes in the mitochondrial genome [68]. Although there is a
lack of investigation regarding mtDNA changes in the context of TBI, platelets could be the
ideal sensor to measure these changes.
We acknowledge several limitations of this study. First, only male mice were used in
these assays. While in the absence of TBI, platelet respiration in humans does not signifi-
cantly vary with sex [43], additional studies are needed to assess sex-specific responses in
the context of TBI. Female animals should be included in future studies to fully encompass
the systemic blood cell response to TBI relative to sex. Blood cell changes were only exam-
ined at 6 and 24 h after injury; future studies should examine whether platelet bioenergetics
are altered chronically following TBI. While hematological analysis was able to uncover
general changes in white blood cell populations after TBI, future studies are needed to
perform FACS phenotyping analysis to examine alterations in specific subsets of leukocytes
in both whole blood and the spleen after CCI and CHI. There are also limitations to the
examination of respiration in intact platelets. Succinate, which has limited cellular uptake,
is given to the intact platelets in this study, so it is difficult to know the affect succinate has
on platelet respiration [69]. Future studies should examine whether cell permeabilization
with direct, unhindered access to mitochondria [43] produces any further insight into
TBI-induced alteration of platelet mitochondrial bioenergetics.
In this study, prostacyclin, which inhibits platelet activation and aggregation, was in
the buffer during the Seahorse experiments. Therefore, the results are indicative of platelet
bioenergetic changes in an inactivated state with potentially altered glucose metabolism.
Future studies, incorporating a wash of prostacyclin before respirometry measurements,
should be performed. Moreover, platelet function may be altered after TBI with the addition
of an activating stimuli, such as ADP or thrombin [70]. Platelets do not have a high reserve
respiratory capacity, especially when compared to other blood cells, such as monocytes
or lymphocytes [42,43]. Here, we show no significant differences between OXPHOS and
MAX levels within our experimental groups. However, Sjovall et al. showed that MAX
rates are significantly lower with the addition of oligomycin compared to those without
oligomycin [43]. This highlights a potential limitation of the present study, though it is
difficult to compare between different respirometry devices.
5. Conclusions
Our findings indicate that CCI produces early blood cell alterations, including low
blood leukocyte levels, dynamic PNA interactions, and alterations in metabolic coupling
in platelets. CHI, however, appears to produce thromboinflammatory effects with high
acute levels of blood leukocytes, slightly elevated PNAs, and delayed increases in platelet
bioenergetics. These mechanisms, related to thromboinflammation, require further explo-
ration, though current results highlight clinically-relevant outcomes following CHI. Finally,
we posit that platelet bioenergetics may have diagnostic and prognostic value, related to
cerebral metabolism, to peripherally monitor progression of TBI.
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